VTRS Viatris

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
• • Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD

Risk Factors

• • FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
• • U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected

Management Discussion & Analysis

• • Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
• • Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment

Management Discussion & Analysis

• • Revenue $3.76B Q3 2025, flat YoY ($3.75B Q3 2024); 9-month revenue $10.60B down 5% YoY ($11.21B 2024)
• • Gross margin decreased to 36% Q3 2025 from 39% Q3 2024; 9-month margin 36% vs 39% YoY due to Indore facility impact

Risk Factors

• • New risk: Potential tariffs up to 15% on brand pharmaceuticals from EU due to new bilateral trade agreements
• • Material update: Increased cost of goods and supply chain disruptions from proposed tariffs on pharmaceutical imports and APIs

What are the latest VTRS SEC filings in 2026?

Viatris (VTRS) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on February 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VTRS file its most recent 10-K annual report?

Viatris (VTRS) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VTRS 10-Q quarterly reports?

Viatris (VTRS)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every VTRS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VTRS filed recently?

Viatris (VTRS)'s most recent 8-K was filed on February 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VTRS insider trading activity (Form 4)?

SignalX aggregates every VTRS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VTRS file with the SEC?

Viatris (VTRS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VTRS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Viatris (VTRS).

What is VTRS's SEC CIK number?

Viatris (VTRS)'s SEC CIK (Central Index Key) number is 1792044. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1792044 to look up all VTRS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VTRS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Viatris (VTRS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.